These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 16728573)

  • 61. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
    Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
    Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
    Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
    Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
    Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 68. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
    Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
    Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modifications in the papillary thyroid cancer gene profile over the last 15 years.
    Romei C; Fugazzola L; Puxeddu E; Frasca F; Viola D; Muzza M; Moretti S; Nicolosi ML; Giani C; Cirello V; Avenia N; Rossi S; Vitti P; Pinchera A; Elisei R
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1758-65. PubMed ID: 22745248
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation.
    Kumagai A; Namba H; Mitsutake N; Saenko VA; Ohtsuru A; Ito M; Noh JY; Sugino K; Ito K; Yamashita S
    Oncol Rep; 2006 Jul; 16(1):123-6. PubMed ID: 16786134
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 74. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
    Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
    Sapio MR; Posca D; Troncone G; Pettinato G; Palombini L; Rossi G; Fenzi G; Vitale M
    Eur J Endocrinol; 2006 Feb; 154(2):341-8. PubMed ID: 16452550
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings.
    Park YJ; Kim YA; Lee YJ; Kim SH; Park SY; Kim KW; Chung JK; Youn YK; Kim KH; Park DJ; Cho BY
    Head Neck; 2010 Jan; 32(1):38-45. PubMed ID: 19475551
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
    Lee JH; Lee ES; Kim YS
    Cancer; 2007 Jul; 110(1):38-46. PubMed ID: 17520704
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular analysis of multifocal papillary thyroid carcinoma.
    Lin X; Finkelstein SD; Zhu B; Silverman JF
    J Mol Endocrinol; 2008 Oct; 41(4):195-203. PubMed ID: 18628356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
    Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
    Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.